5.86
0.43 (7.92%)
0.43 (7.92%)
Upgrade to Real-Time
Afterhours
Volume | 1,132,931 |
|
|||||
News | (1) | ||||||
Day High | 6.635 | Low High |
|||||
Day Low | 5.43 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
First Wave BioPharma Inc | FWBI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.43 | 5.43 | 6.635 | 5.86 | 5.43 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,528 | 1,132,931 | $ 5.97 | $ 6,761,823 | - | 0.8421 - 34.30 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:20:59 | 88 | $ 5.86 | USD |
First Wave BioPharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 5.83M | 995.00k | 993.79k | $ - | $ - | -2,130.03 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | - | 26.50% |
First Wave BioPharma News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FWBI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.77 | 7.49 | 4.35 | 5.39 | 3,903,061 | 1.09 | 22.85% |
1 Month | 5.60 | 8.96 | 3.85 | 5.70 | 2,543,563 | 0.26 | 4.64% |
3 Months | 7.07 | 8.96 | 3.0121 | 5.64 | 1,203,475 | -1.21 | -17.11% |
6 Months | 1.022 | 34.30 | 0.8421 | 9.96 | 1,510,520 | 4.84 | 473.39% |
1 Year | 8.40 | 34.30 | 0.8421 | 5.99 | 1,688,423 | -2.54 | -30.24% |
3 Years | 24.15 | 34.30 | 0.8421 | 8.08 | 1,568,371 | -18.29 | -75.73% |
5 Years | 24.15 | 34.30 | 0.8421 | 8.08 | 1,568,371 | -18.29 | -75.73% |
First Wave BioPharma Description
First Wave BioPharma Inc is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. |